Want to see ENLV full AI Analyst Report?
Top Page
Enlivex
(NASDAQ:ENLV)
Select Model
Select Model
Rating:43Neutral
Price Target:
$6.50
▲(655.81% Upside)
Action:Reiterated
Date:07/11/26
The score is held down primarily by weak financial performance (minimal revenue, sustained operating losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative momentum). Valuation provides only partial offset due to the extremely low P/E, but the sustainability of earnings is unclear given the non-operating nature implied by the 2025 profit spike.
Positive Factors
Low leverage / minimal debt
A very low debt load materially reduces financial risk and preserves strategic optionality over the next several months. For a clinical-stage biotech, low leverage improves the company's ability to raise capital or allocate existing resources to R&D without near-term debt-service constraints, supporting program continuity.
Negative Factors
Persistent negative cash generation
Sustained negative operating and free cash flow means the company remains dependent on external financing to fund trials and operations. Over a multi-month horizon this heightens dilution and execution risk if market conditions or asset realizations (e.g., token liquidity) do not materialize when capital is needed to advance pivotal development milestones.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / minimal debt
A very low debt load materially reduces financial risk and preserves strategic optionality over the next several months. For a clinical-stage biotech, low leverage improves the company's ability to raise capital or allocate existing resources to R&D without near-term debt-service constraints, supporting program continuity.
Read all positive factors
Enlivex (ENLV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$115.47M
Dividend YieldN/A
Average Volume (3M)182.02K
Price to Earnings (P/E)<0.1
Beta (1Y)0.61
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees34
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)405.30
Shares Outstanding16,832,014
10 Day Avg. Volume216,695
30 Day Avg. Volume182,016
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-41.12
Enterprise Value/Ebitda-0.95
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Enlivex Business Overview & Revenue Model
Company Description
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-bas...
How the Company Makes Money
null...
Enlivex Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -332.00K | -545.00K | -835.00K | -777.00K | -546.00K |
| EBITDA | -14.67M | -14.47M | -28.22M | -25.02M | -18.74M |
| Net Income | 1.24B | -15.01M | -29.07M | -31.06M | -14.47M |
Balance Sheet | |||||
| Total Assets | 2.33B | 27.69M | 36.83M | 67.64M | 95.15M |
| Cash, Cash Equivalents and Short-Term Investments | 5.87M | 23.61M | 27.32M | 50.24M | 84.13M |
| Total Debt | 641.00K | 534.00K | 1.03M | 4.85M | 6.01M |
| Total Liabilities | 392.05M | 4.10M | 6.75M | 10.80M | 10.11M |
| Stockholders Equity | 1.93B | 23.59M | 30.08M | 56.84M | 85.04M |
Cash Flow | |||||
| Free Cash Flow | -10.48M | -13.11M | -23.76M | -32.08M | -19.17M |
| Operating Cash Flow | -10.42M | -13.01M | -23.52M | -23.95M | -17.54M |
| Investing Cash Flow | -1.32M | 9.06M | -25.97M | 62.52M | -38.41M |
| Financing Cash Flow | 10.38M | 6.45M | 360.00K | 150.00K | 60.98M |
Enlivex Technical Analysis
Negative
0.86
Price Trends
10.23
Negative
12.68
Negative
13.86
Negative
Market Momentum
-1.02
Positive
21.64
Positive
22.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENLV, the sentiment is Negative. The current price of 0.86 is below the 20-day moving average (MA) of 8.45, below the 50-day MA of 10.23, and below the 200-day MA of 13.86, indicating a bearish trend. The MACD of -1.02 indicates Positive momentum. The RSI at 21.64 is Positive, neither overbought nor oversold. The STOCH value of 22.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENLV.
Enlivex Risk Analysis
Enlivex disclosed 70 risk factors in its most recent earnings report. Enlivex reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enlivex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $15.89M | >-0.01 | -68.21% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $30.26M | -2.01 | 763.44% | ― | ― | ― | |
43 Neutral | $115.47M | 0.02 | 248.08% | ― | ― | ― | |
43 Neutral | $14.68M | -0.38 | -135.04% | ― | ― | 42.29% |
* Healthcare Sector Average
ENLV
Enlivex
6.67
-12.53
-65.26%
DARE
Daré Bioscience
2.09
-1.00
-32.36%
AKTX
Akari Therapeutics
13.40
-30.60
-69.55%
PASG
Passage Bio
4.46
-2.33
-34.32%
Enlivex Corporate Events
Enlivex Sets 1-for-15 Reverse Stock Split Ahead of July 9 Nasdaq Debut
Jul 7, 2026
On February 3, 2026, Enlivex shareholders approved a reverse split of the company’s ordinary shares within a broad ratio range and authorized the board to set the final terms. The board has now fixed the ratio at 1-for-15, with the split to ...
Enlivex’s Primary Treasury Asset RAIN Token set for Listing on Major Exchange Gate
Jun 24, 2026
Enlivex Ltd., a longevity-focused biotech company integrating a prediction markets-based digital treasury, reported that its primary treasury asset, the RAIN token, is a governance and utility token for a decentralized predictions and options prot...
Enlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026
Jun 22, 2026
On June 22, 2026, Enlivex reported that as of June 20 it held 79,568,550,005 RAIN tokens valued at approximately $1.14 billion, underscoring the growing weight of digital assets in its balance sheet. The company said its treasury net asset value p...
Enlivex Values RAIN Token Treasury at $1.16 Billion as Rain Protocol Climbs to No. 3 in Prediction Markets
May 28, 2026
On May 28, 2026, Enlivex reported that as of May 27 it held 79,568,550,005 RAIN tokens in its treasury, valuing its holdings at approximately $1.16 billion and underscoring how central the asset has become to its balance sheet. The update signals ...
Enlivex Highlights $100M Liquidity Boost for Rain as Treasury-Backed Prediction Market Enters Global Top Three
May 27, 2026
On May 27, 2026, Enlivex reported that the Rain Foundation’s new $100 million liquidity commitment to its prediction markets protocol has elevated Rain into the top three global prediction markets by total value locked, alongside Polymarket ...
Enlivex Doses First U.S. Patient in Phase 2b Allocetra Trial for Knee Osteoarthritis
May 18, 2026
On May 18, 2026, Enlivex announced it had dosed the first patient at a U.S. clinical site in its global Phase 2b trial of Allocetra for moderate-to-severe age-related primary knee osteoarthritis, following FDA IND clearance in March and Danish reg...
Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold
May 15, 2026
Enlivex Ltd. is a Nasdaq-listed quality longevity company based in Israel that is advancing Allocetra™, a clinical-stage immunotherapy for aging-related inflammatory conditions, primarily age-related osteoarthritis. The company also operates...
Enlivex Secures Danish Approval for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
Apr 21, 2026
On April 21, 2026, Enlivex announced it received Clinical Trial Application approval from the Danish Medicines Agency to conduct a Phase 2b trial of Allocetra in patients with moderate-to-severe age-related primary knee osteoarthritis. This second...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.